PharmaPoint: Microvascular Complications of Diabetes – France Drug Forecast and Market Analysis to 2022
The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.
The 2012 base-year market sales of products for MCD in France were around $153m. As in the global market, this growth will be fueled by the dramatic increase in prevalence and diagnosis, as well as by the uptake of new branded drugs, such as atrasentan and Optina. The uptake of drugs receiving additional approval for the treatment of diabetic retinopathy/DME, such as Eylea, Iluvien and Ozurdex, will further boost sales in the MCD market.
Scope
- Overview of MCD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in France from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the France MCD market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for MCD
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in France
Table of Contents
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
3 Disease Overview 14
3.1 Etiology and Pathophysiology 16
3.1.1 Diabetic Nephropathy 16
3.1.2 Diabetic Retinopathy 18
3.1.3 Diabetic Neuropathy 19
3.2 Prognosis 20
3.3 Quality of Life 21
3.4 Symptoms 22
4 Disease Management 23
4.1 Treatment Overview 23
4.1.1 Diagnosis and Referrals 23
4.1.2 Screening 25
4.1.3 Treatment Guidelines 26
4.2 France 33
4.2.1 Diagnosis 33
4.2.2 Clinical Practice 35
5 Competitive Assessment 37
5.1 Overview 37
5.2 Strategic Competitor Assessment 38
5.3 Diabetic Nephropathy: Product Profiles - Major Classes and Brands 42
5.3.1 Angiotensin-Converting Enzyme (ACE) Inhibitors 42
5.3.2 Angiotensin Receptor Blockers 45
5.4 Diabetic Retinopathy: Product Profiles - Major Classes and Brands 47
5.4.1 Lucentis (ranibizumab) 47
5.4.2 Avastin (bevacizumab) 52
5.4.3 Corticosteroid Intravitreal Implants 56
5.5 Diabetic Neuropathy: Product Profiles - Major Classes and Brands 59
5.5.1 Tricyclic Antidepressants 59
5.5.2 Serotonin-Norepinephrine Reuptake Inhibitors - Cymbalta (duloxetine) and Effexor (venlafaxine) 62
5.5.3 Anticonvulsants - Neurontin (gabapentin) and Lyrica (pregabalin) 66
5.5.4 Opioids 71
6 Opportunity and Unmet Need 74
6.1 Overview 74
6.2 Unmet Needs 75
6.2.1 Unified Treatment for the Microvascular Complications of Diabetes 75
6.2.2 Optimization of Personalized Therapy in the Microvascular Complications of Diabetes 75
6.2.3 Treatment for Diabetic Nephropathy that Would Prevent ESRD 77
6.2.4 Cardio- and Renoprotective Therapy for Diabetic Nephropathy 78
6.2.5 Efficient Therapy for Retinopathy 79
6.2.6 Convenient Administration in Diabetic Retinopathy Treatment 79
6.2.7 Treatment for Diabetic Neuropathy 80
6.3 Unmet Needs Gap Analysis 81
6.4 Opportunity: Therapy for the Underlying Cause of the Microvascular Complications of Diabetes 83
6.5 Opportunity: Patient-Tailored Therapy for the Microvascular Complications of Diabetes 83
6.6 Opportunity: Efficacious Therapy for Diabetic Nephropathy 84
6.7 Opportunity: Topical Treatment for Diabetic Retinopathy 84
6.8 Opportunity: Treatment for Diabetic Neuropathy 85
7 Pipeline Assessment 86
7.1 Overview 86
7.2 Promising Drugs in Clinical Development 89
7.2.1 Eylea (aflibercept) 91
7.2.2 Optina (danazol) 96
7.2.3 Atrasentan Hydrochloride 101
8 Market Outlook 105
8.1 France 105
8.1.1 Forecast 105
8.1.2 Key Events 110
8.1.3 Drivers and Barriers 110
9 Appendix 114
9.1 Bibliography 114
9.2 Abbreviations 127
9.3 Methodology 132
9.4 Forecasting Methodology 132
9.4.1 Diagnosed Patients 132
9.4.2 Percent Drug-Treated Patients 133
9.4.3 Drugs Included in Each Therapeutic Class 133
9.4.4 Launch and Patent Expiry Dates 133
9.4.5 General Pricing Assumptions 134
9.4.6 Individual Drug Assumptions 135
9.4.7 Generic Erosion 139
9.4.8 Pricing of Pipeline Agents 139
9.5 Physicians and Specialists Included in this Study 140
9.6 About the Authors 142
9.6.1 Analyst II - CVMD 142
9.6.2 Therapy Director - CVMD and Infectious Disease 142
9.6.3 Global Head of Healthcare 143
9.7 About GlobalData 144
9.8 Disclaimer 144
List of Tables
Table 1: Risk Factors for MCD 16
Table 2: Symptoms of MCD 22
Table 3: Diagnostic Tests and Typical Criteria for MCD 24
Table 4: Treatment Guidelines for MCD 27
Table 5: Most Prescribed Drugs for MCD by Class in the 7MM, 2012 30
Table 6: Leading Drug Treatments for MCD, 2013 40
Table 7: ACE Inhibitors SWOT Analysis, 2013 44
Table 8: ARBs SWOT Analysis, 2013 47
Table 9: Product Profile - Lucentis 49
Table 10: Lucentis SWOT Analysis, 2013 51
Table 11: Product Profile - Avastin 53
Table 12: Avastin SWOT Analysis, 2013 55
Table 13: Corticosteroid Intravitreal Implants SWOT Analysis, 2013 58
Table 14: TCAs SWOT Analysis , 2013 61
Table 15: Product Profile - Cymbalta 63
Table 16: Product Profile - Effexor 63
Table 17: Cymbalta SWOT Analysis, 2013 65
Table 18: Product Profile - Neurontin (gabapentin) 68
Table 19: Product Profile - Lyrica (pregabalin) 68
Table 20: Lyrica SWOT Analysis, 2013 70
Table 21: Opioids SWOT Analysis, 2013 73
Table 22: Overall Unmet Needs - Current Level of Attainment 74
Table 23: Clinical Unmet Needs in MCD - Gap Analysis, 2012 82
Table 24: MCD - Clinical Trials by Phase and Status, 2013 88
Table 25: MCD - Phase Pipeline, 2013 89
Table 26: Comparison of Drugs in Development for MCD, 2013 90
Table 27: Product Profile - Eylea 92
Table 28: Eylea SWOT Analysis, 2013 96
Table 29: Product Profile - Optina 98
Table 30: Optina SWOT Analysis, 2013 100
Table 31: Product Profile - Atrasentan 102
Table 32: Atrasentan SWOT Analysis, 2013 104
Table 33: France Sales Forecasts ($) for MCD, 2012-2022 106
Table 34: Key Events Impacting Sales for MCD in France, 2012-2022 110
Table 35: MCD Market - Drivers and Barriers in France, 2013 110
Table 36: Key Launch Dates 133
Table 37: Key Patent Expiries 134
Table 38: Number of High-Prescribing Physicians Surveyed 141
List of Figures
Figure 1: Potential Mechanisms of Diabetes-Induced Microvascular Complications 15
Figure 2: General Treatment Algorithms for MCD 28
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in MCD, 2012-2022 90
Figure 4: Sales for Diabetic Nephropathy in France, 2012-2022 107
Figure 5: Sales for Diabetic Retinopathy in France, 2012-2022 108
Figure 6: Sales for Diabetic Neuropathy in France, 2012-2022 109